Acesulfame potassium induces dysbiosis and intestinal injury with enhanced lymphocyte migration to intestinal mucosa

  • Yoshinori Hanawa
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Masaaki Higashiyama
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Chie Kurihara
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Rina Tanemoto
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Suguru Ito
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Akinori Mizoguchi
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Shin Nishii
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Akinori Wada
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Kenichi Inaba
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Nao Sugihara
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Kazuki Horiuchi
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Yoshikiyo Okada
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Kazuyuki Narimatsu
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Shunsuke Komoto
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Kengo Tomita
    Department of Internal Medicine National Defense Medical College Saitama Japan
  • Ryota Hokari
    Department of Internal Medicine National Defense Medical College Saitama Japan

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aim</jats:title><jats:p>The artificial sweetener acesulfame potassium (ACK) is officially approved as safe for intake and has been used in processed foods. However, ACKs have been reported to induce metabolic syndrome, along with alteration of the gut microbiota in mice. In recent years, studies have suggested that this artificial sweetener promotes myeloperoxidase reactivity in Crohn's disease‐like ileitis. We aimed to investigate the effect of ACK on the intestinal mucosa and gut microbiota of normal mice.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Acesulfame potassium was administered to C57BL/6J mice (8 weeks old) via free drinking. Intestinal damage was evaluated histologically, and messenger RNA (mRNA) levels of TNF‐α, IFN‐γ, IL1‐β, MAdCAM‐1, GLP1R, and GLP2R were determined with quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Immunohistochemistry was performed to examine the expression of MAdCAM‐1 in the small intestine. The composition of gut microbiota was assessed using high‐throughput sequencing. We performed intravital microscopic observation to examine if ACK altered lymphocyte migration to the intestinal microvessels.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Acesulfame potassium increased the expression of proinflammatory cytokines, decreased the expression of GLP‐1R and GLP‐2R, and induced small intestinal injury with an increase in intestinal permeability, and ACK treatment induced microbial changes, but the transfer of feces alone from ACK mice did not reproduce intestinal damage in recipient mice. ACK treatment significantly increased the migration of lymphocytes to intestinal microvessels.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Acesulfame potassium induces dysbiosis and intestinal injury with enhanced lymphocyte migration to intestinal mucosa. Massive use of non‐caloric artificial sweeteners may not be as safe as we think.</jats:p></jats:sec>

収録刊行物

参考文献 (40)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ